The US Food and Drug
Administration (FDA) has reviewed
its recommendation in relation to
the use of Revatio (sildenafil) for
pulmonary arterial hypertension
(PAH).
The FDA states that Revatio is
approved only for PAH in adults,
not in children, but health care
professionals must consider
whether the benefits of treatment
with the drug are likely to outweigh
its potential risks for each patient.The above article was sent to subscribers in Pharmacy Daily's issue from 02 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Apr 14
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.